GlaxoSmithKline (GSK)

How to read and use this data card.

Lobbying costs:

WARNING: As this organisation lists one or more EP accredited lobbyists, it is highly improbable that its lobbying costs are lower than €10,000.

WARNING: The lobbying costs declared by this organisation are extraordinarily high and may therefore have been over-declared.

1,500,000€ - 1,749,000€

Financial year: 01/01/2017 - 01/12/2017

Lobbyists declared: 5.25 FTE (10)

WARNING: The number of full time equivalent lobbyists declared by this organisation are extraordinarily high and may therefore have been over-declared.


Lobbyists with EP accreditation: 6


Meetings with European Commission: 10

Lobbying costs over the years:


GlaxoSmithKline (GSK)

Registration on EU Transparency Register

7990322925-77 (First registered: 06 Jan 2009)

Goals / Remit

GSK is a science-led global healthcare company.

Our purpose is to help people do more, feel better, live longer.

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses (Pharmaceuticals, Vaccines and Consumer Healthcare), scientific and technical know-how and talented people.

Our Pharmaceutical business has a broad portfolio of innovative and established medicines. We currently focus on developing new medicines in respiratory and HIV/infectious diseases, oncology and immuno-inflammation; with discovery research exploring these and other areas.
The business is made up of innovative and established medicines and holds leading market positions in respiratory disease and HIV. In our Pharmaceuticals R&D organisation, almost 80% of research spending focuses on two current therapy areas: respiratory and HIV/infectious diseases; and two potential areas: oncology and immuno-inflammation.

Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. We deliver over two million vaccine doses per day to people living in over 160 countries.
The vaccines in our portfolio have been helping to protect people from serious disease for well over 100 years, with our Marietta (US) site dedicated to smallpox vaccine production since 1882. Today, our vaccines continue to tackle some of the world’s most devastating diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza.
Our Vaccines business has a portfolio of more than 40 vaccines for every stage of life, helping to protect people against 22 diseases. We have a pipeline of 14 candidate vaccines in development. One third of our vaccines in development target diseases particularly prevalent in the developing world, including all three WHO infectious disease priorities: HIV, malaria and TB. Our other vaccines in development include vaccines for the treatment of COPD and prevention of Respiratory Syncytial Virus (RSV).

Our Consumer Healthcare business develops and markets consumer preferred and expert recommended brands in the Oral health, Pain relief, Respiratory, Nutrition/gastro-intestinal and Skin health categories.
We have a portfolio of loved and trusted brands that are underpinned by science including: Sensodyne, Parodontax, Poligrip, Voltaren, Panadol, Otrivin and Theraflu.

We have a significant global presence with commercial operations in more than 150 countries, a network of 86 manufacturing sites in 36 countries and large R&D centres in the UK, USA, Spain, Belgium and China.


We follow EU initiatives, policies and legislative files related to our Pharmaceuticals, Vaccines and Consumer Healthcare businesses. This includes topics such as R&D and clinical trials, antimicrobial resistance, data protection, pharmaceutical legislation, medical devices, trade & IP, environment, smoking cessation.


Head office:
Great West Road, 980
Brentford, Middlesex TW8 9GS,
United Kingdom

Tel: 44 20 8047 5000

Belgium office:
37 Square de Meeûs
Brussels 1000,

Tel: 32 27917600